CAR T-cell therapy for cancer leads to similar safety and cancer outcomes in patients with and without preexisting autoimmune ...
The US researchers at the Baylor College of Medicine, Texas Children’s Hospital have said the follow-up observations mark the ...
Poor physical performance in patients with non-Hodgkin lymphoma receiving CAR T-cell therapy was linked to worse survival and ...
CAR-T cell therapy achieves 18-year survival milestone in cancer patient Innovative cancer treatment shows promise as ...
A patient has achieved over 18 years of remission from neuroblastoma, a type of nerve cell cancer, following treatment with ...
New Scientist on MSN1d
CAR T-cells enable record-breaking 18-year nerve cancer remissionA person with neuroblastoma, which occurs when developing nerve cells in children turn cancerous, has remained tumour-free ...
The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell ...
An 18-year survivor of neuroblastoma, a solid childhood tumor that develops in immature nerve cells, is believed to represent ...
Cellistic, a pioneer in iPSC-based off-the-shelf cell therapy development and manufacturing services, announces the launch of ...
Medical Xpress on MSN15d
No evidence that CAR T cell therapy causes secondary cancers, large study showsWithin a large group of more than 700 patients treated with CAR T cell therapy, researchers found no evidence that the ...
T-cell therapy with ciltacabtagene autoleucel (cilta-cel) in the phase 3 CARTITUDE-4 trial. Monoclonal T cells from both patients had detectable CAR transgene expression and integration.
Not everyone responds to statins, the standard treatment for people at risk of cardiovascular disease, so an alternative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback